文献速递神经免疫

多发性硬化与癌症诊断:乳腺癌和结直肠癌的诊断途径、癌症分期及诊断间期

Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer.
PubMed 文献 · Neurology · 2022-01-01

加拿大安大略省基于行政数据的匹配人群横断面研究显示,多发性硬化(MS)患者乳腺癌筛查检出率较低(OR 0.68),结直肠癌I期检出率较高(OR 2.11),两种癌症的诊断间期中位数在有无MS者间无差异;控制残疾状态后部分结果减弱。

要点

  • MS患者乳腺癌筛查检出几率低于无MS者(OR 0.68,95%CI 0.52-0.88)。
  • MS患者结直肠癌I期诊断几率高于无MS者(OR 2.11,95%CI 1.03-4.30)。
  • 乳腺癌和结直肠癌的诊断间期中位数在有无MS者间均无差异。

核心结论

  • MS患者乳腺癌更少通过筛查检出,结直肠癌更可能在早期阶段检出,MS相关残疾可能妨碍接受乳腺X线和结肠镜检查。

研究设计与样本

  • 基于加拿大安大略省行政数据的匹配人群横断面研究,纳入2007—2015年乳腺癌和2009—2012年结直肠癌患者,MS与非MS按1:4匹配。
  • 乳腺癌队列纳入351例MS患者和1,404例匹配无MS患者;结直肠癌队列纳入54例MS患者和216例匹配无MS患者。

主要发现

  • MS与乳腺癌筛查检出几率降低相关(OR 0.68,95%CI 0.52-0.88),与结直肠癌筛查检出几率可能降低相关(OR 0.52,95%CI 0.21-1.28)。
  • MS与乳腺癌I期诊断无显著关联(OR 0.81,95%CI 0.64-1.04)。
  • MS与结直肠癌I期诊断几率升高相关(OR 2.11,95%CI 1.03-4.30)。
  • 乳腺癌和结直肠癌队列中,有无MS者的诊断间期中位长度均无差异。

局限性

  • 控制残疾状态后部分发现减弱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The multiple sclerosis (MS) population's survival from breast cancer and colorectal cancer is compromised. Cancer screening and timely diagnoses affect cancer survival and have not been studied in the MS cancer population. We investigated whether the diagnostic route, cancer stage, or diagnostic interval differed in patients with cancer with and without MS. METHODS: We conducted a matched population-based cross-sectional study of breast cancers (2007-2015) and colorectal cancers (2009-2012) in patients with MS from Ontario, Canada, using administrative data. Exclusion criteria included second or concurrent primary cancers, no health care coverage, and, for the patients without MS, those with any demyelinating disease. We based 1:4 matching of MS to non-MS on birth year, sex (colorectal only), postal code, and cancer diagnosis year (breast only). Cancer outcomes were diagnostic route (screen-detected vs symptomatic), stage (stage I vs all others), and diagnostic interval (time from first presentation to diagnosis). Multivariable regression analyses controlled for age, sex (colorectal only), diagnosis year, income quintile, urban/rural residence, and comorbidity. RESULTS: We included 351 patients with MS and breast cancer, 1,404 matched patients with breast cancer without MS, 54 patients with MS and colorectal cancer, and 216 matched patients with colorectal cancer without MS. MS was associated with fewer screen-detected cancers in breast (odds ratio [OR] 0.68 [95% CI 0.52, 0.88]) and possibly colorectal (0.52 [0.21, 1.28]) cancer. MS was not associated with differences in breast cancer stage at diagnosis (stage I cancer, OR 0.81 [0.64, 1.04]). MS was associated with greater odds of stage I colorectal cancer (OR 2.11 [1.03, 4.30]). The median length of the diagnostic interval did not vary between people with and without MS in either the breast or colorectal cancer cohorts. Controlling for disability status attenuated some findings. DISCUSSION: Breast cancers were less likely to be detected through screening and colorectal cancer more likely to be detected at early stage in people with MS than without MS. MS-related disability may prevent people from getting mammograms and colonoscopies. Understanding the pathways to earlier detection in both cancers is critical to developing and planning interventions to ameliorate outcomes for people with MS and cancer.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Groome PA, Webber C, Maxwell CJ, et al. Multiple Sclerosis and the Cancer Diagnosis: Diagnostic Route, Cancer Stage, and the Diagnostic Interval in Breast and Colorectal Cancer. Neurology. 2022. PMID: 35501160. doi:10.1212/WNL.0000000000200163

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。